The RESCUE BT3 trial is an ongoing protocol designed to evaluate whether early intravenous tirofiban administration after thrombolysis improves functional outcomes in patients with acute ischaemic stroke.
RCT (n=1,314)
Double-blind
1:1 ratio
Yes
Does early intravenous tirofiban administration improve functional outcomes at 90 days in acute ischaemic stroke patients without large or medium vessel occlusion who have persistent disability after intravenous thrombolysis?
The RESCUE BT3 trial will evaluate whether early administration of intravenous tirofiban improves functional outcomes in acute ischaemic stroke patients without large or medium vessel occlusion who have persistent disability after intravenous thrombolysis.
Abstract Background Intravenous thrombolysis (IVT) is the standard first-line treatment for patients with acute ischaemic stroke (AIS). However, a significant number of these patients fail to achieve favourable functional outcomes. Early administration of tirofiban may improve functional outcomes in patients who fail to respond to IVT. Study design The RESCUE BT3 trial is a multicentre, randomised, double-blind, placebo-controlled trial. A total of 1314 AIS patients without large or medium vessel occlusion and with persistent disability after IVT will be randomised in a 1:1 ratio to receive intravenous tirofiban or placebo within 2–24 h after completion of IVT. Study endpoints The primary efficacy endpoint is the proportion of patients achieving an excellent functional outcome (mRS score 0–1) at 90 days. Secondary endpoints include functional independence (mRS 0–2), ordinal mRS shift, NIHSS change and quality-of-life measures. Safety outcomes include sICH within 48 h and all-cause mortality at 90 days. Summary This trial aims to determine whether early tirofiban administration after IVT improves functional outcomes without increasing haemorrhagic risk in AIS patients without large or medium vessel occlusion. The results will provide high-quality evidence for adjunctive antiplatelet therapy in this population. Trial registration chiCTR2400080653 (www.chictr.org.cn).
Li et al. (Mon,) conducted a rct in Acute ischaemic stroke (n=1,314). Intravenous tirofiban vs. Placebo was evaluated on Proportion of patients achieving an excellent functional outcome (mRS score 0-1) at 90 days. The RESCUE BT3 trial is an ongoing protocol designed to evaluate whether early intravenous tirofiban administration after thrombolysis improves functional outcomes in patients with acute ischaemic stroke.